The New England Journal of Medicine JULY 13, 2017

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gunter von Minckwitz, Marc Procter, Evandro de Azambuja, Dimitrios Zardavas, et al.

Bottom Line

The APHINITY trial demonstrated that the addition of pertuzumab to standard adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival in patients with HER2-positive early breast cancer, with the benefit primarily driven by the node-positive cohort.

Key Findings

1. At the primary analysis, the 3-year invasive disease-free survival (iDFS) was 94.1% in the pertuzumab group compared to 93.2% in the placebo group (hazard ratio, 0.81; 95% CI, 0.66 to 1.00; P=0.045).

2. Subgroup analysis revealed a notable benefit in patients with node-positive disease, where the 3-year iDFS was 92.0% with pertuzumab versus 90.2% with placebo (hazard ratio, 0.77).

3. In patients with node-negative disease, no significant benefit was observed, with 3-year iDFS of 97.5% in the pertuzumab arm and 98.4% in the placebo arm.

4. The addition of pertuzumab was associated with a higher incidence of diarrhea (all grades: 71.2% vs 45.2%) compared to the placebo group, although cardiac safety profiles were similar between the arms.

5. Long-term follow-up at 8.4 years continued to show a robust iDFS benefit in the node-positive cohort (8-year iDFS 86.1% vs 81.2%; HR 0.72) but failed to show a statistically significant overall survival benefit.

Study Design

Design

RCT

Double-Blind

Sample

4,804

Patients

Duration

8.4 yr

Median

Setting

Multicenter, Global

Population Adults with operable, HER2-positive primary breast cancer (node-positive or high-risk node-negative).

Intervention One year of pertuzumab (840 mg loading, then 420 mg) plus trastuzumab and standard chemotherapy.

Comparator One year of placebo plus trastuzumab and standard chemotherapy.

Outcome Invasive disease-free survival (iDFS), defined as time to recurrence of invasive breast cancer or death from any cause.

Study Limitations

• The absolute improvement in iDFS for the overall population was relatively modest at 3 years, necessitating careful patient selection for the addition of pertuzumab.

• Lack of a statistically significant overall survival benefit despite prolonged follow-up.

• Increased toxicity, specifically diarrhea, associated with the addition of a second monoclonal antibody.

• The trial was not powered to detect small differences in low-risk, node-negative subgroups, limiting the generalizability of the benefit to this population.

Clinical Significance

The APHINITY trial established the dual HER2-blockade (pertuzumab plus trastuzumab) as a standard-of-care adjuvant regimen for high-risk, node-positive HER2-positive early breast cancer. It refined clinical practice by helping clinicians reserve this more intensive and costly therapy for patients who derive the most substantial absolute risk reduction, while avoiding potential over-treatment in lower-risk node-negative patients.

Historical Context

The study followed the success of the pivotal CLEOPATRA trial, which demonstrated that adding pertuzumab to trastuzumab and docetaxel significantly improved progression-free and overall survival in metastatic HER2-positive breast cancer. APHINITY sought to translate this success into the adjuvant, curative-intent setting, reflecting a broader trend in oncology toward integrating dual-targeted therapies early in the treatment algorithm.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the molecular mechanism of action of pertuzumab, and how does it differ from trastuzumab in the treatment of HER2-positive breast cancer?

Key Response

Trastuzumab binds to the extracellular domain IV of HER2, inhibiting downstream signaling and inducing antibody-dependent cellular cytotoxicity. Pertuzumab binds to domain II (the dimerization domain), preventing HER2 from forming heterodimers with other HER family members, particularly HER3. This dual blockade provides a more comprehensive inhibition of the PI3K/Akt pathway than either agent alone.

Resident

Based on the long-term follow-up of the APHINITY trial, which clinical subgroup demonstrates a clear benefit from the addition of adjuvant pertuzumab, and how does this affect your management of a patient with a T1cN0 HER2-positive tumor?

Key Response

The benefit of adding pertuzumab was primarily driven by the node-positive cohort (HR 0.72 in later updates). In the node-negative cohort, there was no statistically significant improvement in invasive disease-free survival (iDFS). Therefore, for a T1cN0 patient, standard chemotherapy plus trastuzumab (or the APT trial regimen of paclitaxel/trastuzumab) is often preferred to avoid the added toxicity and cost of pertuzumab without clear evidence of benefit.

Fellow

How should the APHINITY trial results be integrated into the treatment algorithm for a patient who has completed neoadjuvant therapy and has residual disease at the time of surgery?

Key Response

The APHINITY trial evaluated adjuvant dual blockade in a largely neoadjuvant-naive population. However, the KATHERINE trial subsequently showed that for patients with residual disease after neoadjuvant HER2-targeted therapy, switching to T-DM1 is superior to continuing trastuzumab. Current practice dictates that if a patient remains high-risk (residual disease), T-DM1 is the standard, whereas the APHINITY pertuzumab/trastuzumab regimen is typically reserved for those who did not receive neoadjuvant therapy but are found to be node-positive at surgery.

Attending

Considering the modest absolute iDFS benefit (approximately 2.8% at 8 years for the node-positive group), how do you incorporate the concept of 'financial toxicity' and diarrhea-related morbidity into the shared decision-making process for adjuvant dual blockade?

Key Response

Attendings must balance statistical significance with clinical meaningfulness. The absolute benefit is small, particularly in the overall population. Discussion should include the high cost of an additional year of pertuzumab and the significantly higher rate of Grade 3 diarrhea (9.8% vs 3.7%) compared to trastuzumab alone, ensuring the patient's values regarding risk reduction versus quality of life are prioritized.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The APHINITY trial utilized invasive disease-free survival (iDFS) as its primary endpoint. Critically evaluate whether iDFS is a sufficiently robust surrogate for Overall Survival (OS) in the context of modern HER2-targeted salvage therapies.

Key Response

While iDFS allows for earlier assessment of trial results, its correlation with OS has weakened in the HER2+ space because patients with metastatic recurrence now survive significantly longer due to agents like T-DM1, tucatinib, and trastuzumab deruxtecan. This 'dilution' of the survival signal means that a treatment can improve iDFS without ever showing a statistically significant OS benefit, raising questions about the long-term value of the intervention.

Journal Editor

A major critique of the APHINITY trial was the very high performance of the control arm. How does the higher-than-expected iDFS in the trastuzumab-only arm affect the statistical power of the study and the clinical interpretation of the hazard ratios?

Key Response

The trial was powered based on an expected lower iDFS in the control group. Because the trastuzumab-only arm performed exceptionally well, the absolute difference between groups was smaller than anticipated (under 2% initially). This forces a shift in focus from 'is it better?' to 'is the degree of improvement worth the resource utilization?', a common editorial challenge in trials of already highly effective therapies.

Guideline Committee

In view of the APHINITY results, how should the guidelines reconcile the recommendation for dual HER2 blockade in node-positive disease with the lack of benefit in the hormone receptor-positive versus negative subgroups over time?

Key Response

Current guidelines (NCCN, ASCO) recommend adjuvant pertuzumab for node-positive disease regardless of hormone receptor (HR) status. However, APHINITY data initially suggested a more pronounced benefit in HR-negative patients. Committees must decide if the evidence is strong enough to limit pertuzumab use to HR-negative/node-positive patients or if the modest benefit across all node-positive patients justifies a broad recommendation despite the rising costs of cancer care.

Clinical Landscape

Noteworthy Related Trials

2005

HERA Trial

n = 5,102 · NEJM

Tested

Trastuzumab for 1 or 2 years

Population

HER2-positive early breast cancer patients after adjuvant chemotherapy

Comparator

Observation

Endpoint

Disease-free survival

Key result: Trastuzumab treatment for one year significantly improved disease-free survival compared with observation.

2005

BCIRG 006 Trial

n = 3,222 · NEJM

Tested

Doxorubicin, cyclophosphamide, and docetaxel (AC-TH) or docetaxel, carboplatin, and trastuzumab (TCH)

Population

HER2-positive early breast cancer patients

Comparator

Doxorubicin, cyclophosphamide, and docetaxel (AC-T)

Endpoint

Disease-free survival

Key result: The addition of trastuzumab to adjuvant chemotherapy significantly improved disease-free and overall survival in HER2-positive breast cancer patients.

2012

CLEOPATRA Trial

n = 808 · NEJM

Tested

Pertuzumab plus trastuzumab and docetaxel

Population

HER2-positive metastatic breast cancer patients

Comparator

Placebo plus trastuzumab and docetaxel

Endpoint

Progression-free survival

Key result: The addition of pertuzumab to trastuzumab and docetaxel resulted in a significant improvement in progression-free and overall survival in the metastatic setting.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis